An Atlanta-based biotech company last week said it successfully concluded the first-ever clinical trial testing of a microarray injection-free vaccine on children as young as 9 months old.

Micron Biomedical tested microneedle-based delivery of the measles-rubella (MR) vaccine on children in Gambia with backing from the Bill & Melinda Gates Foundation and the Centers for Disease Control and Prevention (CDC).

Microarray injections are administered via a microneedle patch that looks like a Band-Aid and is applied by pressing it to the skin. Once applied, microneedles penetrate the upper layer of the skin to deliver the vaccine.

The study, which researchers presented last week at the Microneedles 2023 conference in Seattle, evaluated the safety, immunogenicity and acceptability of the leading commercially available MR vaccine from the Serum Institute of India delivered by Micron’s microarray technology in adults, toddlers and infants.  (See link for article)



  • Lots of money is exchanging hands and the market for the flu vaccine alone is projected to reach $2.3 billion by 2030.
  • Trials for vaccine patches against COVID-19seasonal influenza and hepatitis B also are ongoing, while patches against human papillomavirus, typhoid and rotavirus are in preclinical development.
  • Dr. Francis Collins, then-director of the National Institutes of Health, chairs the White House panel discussion and is in on it.
  • Of course it’s all touted as “safe and effective,” just like every other vaccine despite reality.
  • The new technology will predictably be rolled out on children in Africa.
  • Scholars have raised questions and have published a paper raising concerns about lack accountability on large scale clinical trials of untested or unapproved drugs where administering drugs is less regulated and cheaper.
  • Even the corrupt Lancet’s editorial board raised questions about Gates-funded research in low-income settings, pointing to the foundation’s limited transparency and tremendous power to direct health programs and research with its funding.